51 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
on sales and marketing strategy will be made at a later date.
Pricing
We have not conducted a formal pricing analysis of DCCR in PWS. We anticipate
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
and marketing strategy will be made at a later date.
Pricing
We have not conducted a formal pricing analysis of DCCR in PWS. We anticipate that pricing
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
. With our strengthened leadership team and balance sheet, we are ideally positioned to carry out our corporate strategy and, if approved, deliver a new
424B5
pfvmr96x4
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
eq5wm egz0f
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
a4boh
16 Aug 23
Departure of Directors or Certain Officers
9:00am
424B5
v2h1a5v
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
24devdii
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
ueiv47yte5q3iox41lpp
16 Jul 21
Prospectus supplement for primary offering
4:07pm